Crinetics Pharmaceuticals
CRNX
111 hedge funds and large institutions have $885M invested in Crinetics Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 46 increasing their positions, 31 reducing their positions, and 17 closing their positions.
51,340% more call options, than puts
Call options by funds: $2.57M | Put options by funds: $5K
48% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.1% less ownership
Funds ownership: 95.75% → 94.65% (-1.1%)
4% less funds holding
Funds holding: 116 → 111 (-5)
11% less capital invested
Capital invested by funds: $995M → $885M (-$110M)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$22.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$13.5M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$13.1M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.75M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$9.01M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.99M |
| 4 |
ACM
Altium Capital Management
New York
|
-$4.48M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.87M |
CRNX Hedge Fund Activity: Q2 2022 in Review
111 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q2 2022, worth a combined $885M — down 11% from $995M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CRNX and 15 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 46 added.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $22.5M. The largest seller was Deep Track Capital, cutting an estimated $9.75M.
- 111 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q2 2022, down from 116 in Q1 2022.
- Funds reported $885M of Crinetics Pharmaceuticals stock for Q2 2022, down 11% quarter-over-quarter.
- 15 funds opened new Crinetics Pharmaceuticals positions in Q2 2022 and 17 closed out, a net change of -2 holders.
- The largest Crinetics Pharmaceuticals buyer in Q2 2022 was Suvretta Capital Management, an estimated $22.5M added.
- The largest Crinetics Pharmaceuticals seller in Q2 2022 was Deep Track Capital, an estimated $9.75M sold.
Based on aggregated 13F filings for Q2 2022.